高级检索
当前位置: 首页 > 详情页

Ropivacaine Inhibits Lung Cancer Cell Malignancy Through Downregulation of Cellular Signaling Including HIF-1 alpha In Vitro

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Hebei Med Univ, Dept Anesthesiol, Hosp 4, Shijiazhuang, Peoples R China [2]Hebei Med Univ, Dept Blood Transfus, Hosp 4, Shijiazhuang, Peoples R China [3]Hebei Med Univ, Sci Res Ctr, Hosp 4, Shijiazhuang, Peoples R China
出处:
ISSN:

关键词: ropivacaine HIF-1 alpha non-small-cell lung cancer (NSCLC) local anesthetics proliferation migration invasion

摘要:
Background: Ropivacaine is widely used to induce regional anesthesia during lung cancer surgery. Previous studies reported that amide-linked local anesthetics, e.g., ropivacaine, affected the biological behavior of lung adenocarcinoma cells, but the conclusion is controversial and warrants further study. This study set out to investigate the biological effects of ropivacaine on cultured lung cancer cells and underlying mechanisms.Methods: Lung cancer cell lines (A549 and H1299) were cultured and then treated with or without ropivacaine (0.5, 1, and 2 mM) for 48 or 72 h. Their proliferation, migration, and invasion together with cell death and molecules including hypoxia inducible factor (HIF)-1 alpha, VEGF, matrix metalloproteinase (MMP)-1, MMP-2, and MMP-9 expression associated with these changes were determined.Results: Ropivacaine significantly inhibited proliferation and migration, invasion, and cell death in a concentration-dependent manner in both cell lines. Ropivacaine also promoted cell death and induced a concentration- and time-dependent cell arrest towards the G0/G1 phase. Expression of VEGF, MMP-1, MMP-2, MMP-9, and HIF-1 alpha in both cell lines was also inhibited by ropivacaine in a concentration-related manner.Conclusion: Our data indicated that ropivacaine inhibited lung cancer cell malignancy, which may be associated with downregulation of cell-survival-associated cellular molecules. The translational value of the current work is subjected to further study.

基金:

基金编号: 2019YX010A

语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2022]版:
大类 | 2 区 医学
小类 | 2 区 药学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 药学
JCR分区:
出版当年[2022]版:
Q1 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者:
第一作者机构: [1]Hebei Med Univ, Dept Anesthesiol, Hosp 4, Shijiazhuang, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]Hebei Med Univ, Dept Anesthesiol, Hosp 4, Shijiazhuang, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:39770 今日访问量:0 总访问量:1333 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号